Application of a scoring system based on immune gene pairs in predicting the effect of immunotherapy in patients with non-small cell lung cancer

A non-small cell lung cancer and gene pairing technology, applied in the field of biomedicine, can solve the problems of low clinical application value, small sample overfitting, lack of validation, etc.

Active Publication Date: 2022-06-28
CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are also studies that use gene expression characteristics to predict treatment-sensitive patients, but due to the limitation of the analysis platform, the clinical application value is not high
One of the reasons is that traditional research is based on gene expression levels, and these data need to be adequately standardized. However, due to technical bias and biological heterogeneity, there will always be problems such as small sample overfitting and lack of sufficient validation.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of a scoring system based on immune gene pairs in predicting the effect of immunotherapy in patients with non-small cell lung cancer
  • Application of a scoring system based on immune gene pairs in predicting the effect of immunotherapy in patients with non-small cell lung cancer
  • Application of a scoring system based on immune gene pairs in predicting the effect of immunotherapy in patients with non-small cell lung cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Example 1. Application of IRGPI in predicting the efficacy and prognosis of anti-PD-1 immunotherapy for non-small cell lung cancer 1. Research subjects

[0047] The information of the research subjects is shown in Table 1, which are divided into three cohorts, namely the GSE93157 cohort, the GSE136961 cohort and the CICAMS cohort.

[0048] Table 1. Information on research objects

[0049]

[0050]

[0051] Among them, the GSE93157 cohort mainly included patients with advanced thoracic malignancies who were treated with anti-PD-1 antibodies at Hebron Valley Hospital and Barcelona University Hospital in Spain. Inclusion criteria were: 1) patients with clinically diagnosed locally advanced or locally advanced non-small cell lung cancer; 2) received immunotherapy for the first time, with no limit on the number of lines of treatment; 3) both in Hebron Valley Hospital and Barcelona in Spain before immunotherapy Lung cancer surgery is performed at the University Hospita...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of a scoring system based on immune gene pairs in predicting the curative effect and prognosis of immunotherapy for patients with non-small cell lung cancer. The scoring system disclosed in the present invention is based on the following four immune-related gene pairs: CCL2 and VEGFA gene, CDK1 and CXCL9 gene, HLA-DOB and LCK gene, IL-12A and TBX21 gene. The IRGP index (IRGPI) calculated based on the immune gene pair scoring system constructed in the present invention is significantly correlated with the progression-free survival of non-small cell lung cancer patients receiving anti-PD‑1 immunotherapy. It shows that using the 4 immune-related gene pairs of the present invention and the scoring system constructed based on these 4 immune-related gene pairs can predict the curative effect and prognosis of non-small cell lung cancer patients receiving anti-PD-1 immunotherapy.

Description

technical field [0001] The invention relates to the application of predicting the immunotherapy effect of non-small cell lung cancer patients based on an immune gene pair scoring system in the field of biomedicine. Background technique [0002] Lung cancer is a malignant tumor with the highest morbidity and mortality in China and even in the world. According to histopathological classification, non-small-cell lung cancer (NSCLC) accounts for about 85% and is the most common histological type. In recent years, immunotherapy targeting the immune checkpoint programmed death-1 (PD-1) and its ligand (PD-1 ligand, PD-L1) has become the most popular tumor therapy after molecular targeted therapy. means to rapidly change the treatment paradigm of NSCLC. Recent clinical trials and real-world studies have demonstrated long-term survival benefits for patients with immunotherapy, but in limited populations. Therefore, there is an urgent need for reliable markers to screen out this pa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6886G01N33/574G16B30/00
CPCC12Q1/6886G01N33/57423G01N33/57484G16B30/00C12Q2600/158C12Q2600/118C12Q2600/106G01N2800/52
Inventor 赫捷孙楠刘澄铭王思慧
Owner CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap